Platelet Activating Factor
"Platelet Activating Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION.
| Descriptor ID |
D010972
|
| MeSH Number(s) |
D02.033.100.291.211.500 D02.092.063.291.211.500 D02.092.877.883.333.710 D02.675.276.232.710 D10.570.755.375.760.400.985.910 D23.119.865 D23.469.050.600
|
| Concept/Terms |
Platelet Activating Factor- Platelet Activating Factor
- Factor, Platelet Activating
- Phosphorylcholine, Acetyl Glyceryl Ether
- Platelet Aggregating Factor
- Aggregating Factor, Platelet
- Platelet Aggregation Enhancing Factor
- AGEPC
- Thrombocyte Aggregating Activity
- 1-Alkyl-2-acetyl-sn-glycerophosphocholine
- 1 Alkyl 2 acetyl sn glycerophosphocholine
- Acetyl Glyceryl Ether Phosphorylcholine
- PAF-Acether
- PAF Acether
- Platelet-Activating Substance
- Platelet Activating Substance
|
Below are MeSH descriptors whose meaning is more general than "Platelet Activating Factor".
Below are MeSH descriptors whose meaning is more specific than "Platelet Activating Factor".
This graph shows the total number of publications written about "Platelet Activating Factor" by people in this website by year, and whether "Platelet Activating Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Platelet Activating Factor" by people in Profiles.
-
Platelet-activating factor-induced chemokine gene expression requires NF-kappaB activation and Ca2+/calcineurin signaling pathways. Inhibition by receptor phosphorylation and beta-arrestin recruitment. J Biol Chem. 2004 Oct 22; 279(43):44606-12.
-
Clinically relevant hypertonicity prevents stored blood- and lipid-mediated delayed neutrophil apoptosis independent of p38 MAPK or caspase-3 activation. Surgery. 2003 Jul; 134(1):86-91.
-
Distinct roles of receptor phosphorylation, G protein usage, and mitogen-activated protein kinase activation on platelet activating factor-induced leukotriene C(4) generation and chemokine production. J Biol Chem. 2002 Jun 21; 277(25):22685-91.
-
Blood transfusion and the two-insult model of post-injury multiple organ failure. Shock. 2001 Apr; 15(4):302-6.
-
Hypertonic saline inhibits neutrophil (PMN) priming via attenuation of p38 MAPK signaling. Shock. 2000 Sep; 14(3):265-9; discussion 269-70.
-
Fluorescein derivatization of fibrinogen for flow cytometric analysis of fibrinogen binding to platelets. Cytometry. 1994 Dec 01; 17(4):287-93.
-
Synthesis of 1-acyl-2-[3H]acetyl-SN-glycero-3-phosphocholine, a structural analog of platelet activating factor, by vascular endothelial cells. Biochem Biophys Res Commun. 1991 May 15; 176(3):1557-64.